The estimated Net Worth of Malcolm G Witter is at least $98 dollars as of 17 September 2021. Malcolm Witter owns over 20,000 units of Navidea Biopharmaceuticals Inc stock worth over $98 and over the last 4 years Malcolm sold NAVB stock worth over $0.
Malcolm has made over 6 trades of the Navidea Biopharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Malcolm bought 20,000 units of NAVB stock worth $32,000 on 17 September 2021.
The largest trade Malcolm's ever made was buying 21,500 units of Navidea Biopharmaceuticals Inc stock on 29 March 2021 worth over $44,505. On average, Malcolm trades about 3,932 units every 12 days since 2020. As of 17 September 2021 Malcolm still owns at least 98,257 units of Navidea Biopharmaceuticals Inc stock.
You can see the complete history of Malcolm Witter stock trades at the bottom of the page.
Malcolm's mailing address filed with the SEC is 4995 BRADENTON AVE., SUITE 240, , DUBLIN, OH, 43017.
Over the last 13 years, insiders at Navidea Biopharmaceuticals Inc have traded over $3,167,813 worth of Navidea Biopharmaceuticals Inc stock and bought 7,718,496 units worth $6,241,151 . The most active insiders traders include John K Jr. Scott, Perry A Karsen et Life Sciences, Llc Platinum.... On average, Navidea Biopharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of $159. The most recent stock trade was executed by John K Jr. Scott on 10 April 2022, trading 3,260 units of NAVB stock currently worth $3.
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Navidea Biopharmaceuticals Inc executives and other stock owners filed with the SEC include: